MedPath

Double-Blind, Placebo-Controlled Study for the Effect of Daily Ingestion of the Tea Containing Enzymatically Modified Rutin on Lipid Metabolism Improvement

Phase 3
Conditions
Healthy adults
Registration Number
JPRN-UMIN000017204
Lead Sponsor
Hokkaido Information University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
64
Inclusion Criteria

Not provided

Exclusion Criteria

1.Subjects who are under treatment and medication for hyperlipidemia, diabetes and/or hypertension 2. Subjects with serious cerebrovascular, cardiac, hepatic, renal, and / or gastrointestinal diseases, or affected with an infectious disease which is required to report to the authorities 3.Subjects who have a major surgical history related to digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 4. Subjects with unusually high and/or low blood pressure or abnormal hematological data 5. Subjects with serious anemia 6. Pre- or post-menopausal subjects having complaints of obvious physical changes 7. Subjects who are at risk of having allergic reactions to drugs or foods (especially tea) 8. Subjects regularly take medicine , functional foods and/or supplements (EPA, DHA, MCT, phytosterol, sesamin, turmeric, polyphenols, and/or dietary fiber, etc.) which would affect the blood lipids. 9. Subjects regularly take medicine functional foods and/or supplements based on dietary fiber from resistant dextrin, and/or polyphenols, etc. which would affect the blood glucose. 10. Subjects regularly take medicine, functional foods and/or supplements ( peptide, acetic acid, GABA, geniposidic acid, flavonoids, sesamin, chlorella, olive leaves, garlics, dietary fiber, tomatoes, folic acid, etc.) which would affect the blood pressure. 11. Heavy smokers, alcohol addicts or subjects with irregular lifestyle 12. Subjects who donate either 400ml whole blood within 12 weeks or 200ml whole blood within 4 weeks or blood components within 2 weeks prior to this study. 13. Subjects who are pregnant or expected to be pregnant, or lactating during the study 14. Subjects who participate in other clinical trials within the last one month prior to the current clinical trial 15. Any other medical reasons judged by the the principal investigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
DL-Cho
Secondary Outcome Measures
NameTimeMethod
T-Cho, HDL-Cho, TG, NEFA, phospholipid, fasting blood glucose, HbA1c, glycoalbumin, pentosidine oxo-LDL, TBARS, blood-pressure
© Copyright 2025. All Rights Reserved by MedPath